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CD93 is a marker for LSCs in CML, but its
broad expression on normal tissue
hinders the development of CD93-
targeting therapies. Riether et al. show
that signaling via the intracellular domain
of CD93 selectively promotes self-
renewal of LSCs and that this process can
be inhibited with the anti-emetic drug
metoclopramide.
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https://doi.org/10.1016/j.celrep.2020.108663SUMMARYSelf-renewal is a key characteristic of leukemia stem cells (LSCs) responsible for the development and main-
tenance of leukemia. In this study, we identify CD93 as an important regulator of self-renewal and prolifera-
tion of murine and human LSCs, but not hematopoietic stem cells (HSCs). The intracellular domain of CD93
promotes gene transcription via the transcriptional regulator SCY1-like pseudokinase 1 independently of
ligation of the extracellular domain. In a drug library screen, we identify the anti-emetic agentmetoclopramide
as an efficient blocker of CD93 signaling. Metoclopramide treatment reducesmurine and human LSCs in vitro
and prolongs survival of chronic myeloid leukemia (CML) mice through downregulation of pathways related
to stemness and proliferation in LSCs. Overall, these results identify CD93 signaling as an LSC-specific regu-
lator of self-renewal and proliferation and a targetable pathway to eliminate LSCs in CML.INTRODUCTION
Leukemia stem cells (LSCs) have been characterized as the leu-
kemia-initiating cells in acute myeloid leukemia (AML), chronic
myeloid leukemia (CML), and other hematological neoplasms
(Holyoake and Vetrie, 2017; Lapidot et al., 1994). In CML,
LSCs are found in the majority of patients in the lineage-negative
(Lin) CD34+CD38 fraction of bone marrow (BM) cells, which is
phenotypically similar to normal hematopoietic stem cells
(HSCs) (Holyoake and Vetrie, 2017; Riether et al., 2015a). The
introduction of BCR-ABL1-targeting tyrosine kinase inhibitors
(TKIs) has revolutionized the treatment of CML. In chronic
phase, CML patients often reach deep molecular remissions
by treatment with first- or second-generation TKIs (Bhatia
et al., 2003; Chu et al., 2011). A subgroup of these patients
can successfully discontinue TKI therapy and maintain a treat-
ment-free remission (Laneuville, 2017). However, TKI-insensitive
LSCs persist in the majority of patients over a prolonged time
period (Holyoake and Vetrie, 2017). These quiescent, self-re-
newing LSCs in the BM are the major cause of relapse after
drug discontinuation or by the acquisition of mutations leadingC
This is an open access article under the CC BY-Nto TKI resistance (Holyoake and Vetrie, 2017; Jabbour et al.,
2013; Savona and Talpaz, 2008).
CD93 (C1qRp) is a C-type lectin-like type I transmembrane
protein (Greenlee et al., 2008; Dean et al., 2000; Nepomuceno
et al., 1997). Cleavage products of the intracellular domain
(ICD) of CD93 have been detected in the cytoplasm of human
monocytes after activation of protein kinase C (PKC) signaling
(Bohlson et al., 2005a; Greenlee et al., 2009). The ICD of CD93
contains a nuclear localization signal that is thought to regulate
gene expression by acting as a transcription factor in complex
with other transcription factors (Cokol et al., 2000). CD93 is pref-
erentially expressed on endothelial cells (ECs), platelets, myeloid
cells, and early B cell precursors, but not lymphoid cells (Dean
et al., 2000, 2001; Løvik et al., 2000; McKearn et al., 1985; Nepo-
muceno et al., 1997). In addition, CD93 is expressed on multipo-
tent HSCs of the fetal liver and yolk sac (Huang and Auerbach,
1993) but is absent or very low on normal adult HSCs (Kinstrie
et al., 2020). CD93 signaling is involved in many biological pro-
cesses such as angiogenesis (Khan et al., 2017; Lorenzon
et al., 2012; Petrenko et al., 1999), antibody production, and




OPEN ACCESSas well as the engulfment of apoptotic cells in vivo (Norsworthy
et al., 2004). CD93 was identified as a marker for human CML
LSCs that persist after TKI therapy (Kinstrie et al., 2020). In addi-
tion, CD93 signaling has been shown to induce proliferation and
disease progression in AML LSCs carrying the MLL gene rear-
rangement (Iwasaki et al., 2015; Saito et al., 2010).
The ligands for CD93 are largely unknown. Initially, CD93 was
thought to be a receptor for the complement factor C1q (Nepo-
muceno et al., 1997; Norsworthy et al., 2004). However, McGreal
et al. reported that the CD93 receptor does not bind to C1q
(McGreal and Gasque, 2002; McGreal et al., 2002). Instead,
the EC-specific extracellular matrix protein multimerin 2
(MMRN2) has been recently identified as a potential ligand for
CD93 and other receptors such as C-type lectin-domain-con-
taining 14A (CLEC14A) and CD248 in HEK293 T cells (Khan
et al., 2017).
Based on the documented expression of CD93 on LSCs, the
aim of this study was to define its function in CML. CD93 is ex-
pressed on leukemia stem/progenitor cells (LSPCs), but not on
more differentiated leukemia granulocytes. CD93 signaling pro-
motes self-renewal and proliferation of LSCs, leading to disease
progression in amurine CMLmodel. RNA sequencing (RNA-seq)
analysis reveals that CD93 signaling induces a stem-cell-mainte-
nance- and proliferation-promoting gene expression program.
Interestingly, the ICD of CD93 promotes gene transcription via
the transcriptional regulator SCY1-like pseudo-kinase 1
(SCYL1) independently of ligand binding to the extracellular
domain of CD93. Genetic ablation of CD93 signaling reduces
the frequency of LSCs and prevents CML disease development
in mice. Comparable to the results in murine CML, CD93 is ex-
pressed on human CML LSPCs, triggers the expression of genes
involved in self-renewal and proliferation, and promotes colony
formation in vitro. In a drug library screen, we identify metoclo-
pramide (MCP) as an inhibitor of CD93-signaling in LSCs. MCP
treatment reduces murine and human LSCs and prolongs sur-
vival of CML mice. These results identify CD93 as an important
regulator of stemness of CML LSCs and a potential therapeutic
target and the anti-emetic agent MCP as a drug that blocks
CD93 signaling in CML.
RESULTS
CD93 signaling regulates self-renewal of LSCs
We analyzed the expression of CD93 on LSCs and leukemia pro-
genitor cell populations in a murine retroviral transduction/trans-
plantation CML model (Neering et al., 2007; Riether et al.,
2015b). All LSC subsets (long-term LSCs [LT-LSCs], short-term
LSCs [ST-LSCs], leukemia multipotent progenitor 1 [L-MPP1],
and L-MPP 2) express CD93. In contrast, CD93 expression is
lost onmoredifferentiatedLinSca-1c-kithi leukemicprogenitors
and leukemicGR-1+granulocytes (Figures1A,1B, andS1A). Simi-
larly, all subpopulations of the LinSca-1+c-kithi (LSK) fraction in
the BM of naive mice (HSCs, multipotent progenitors [MPPs],
and hematopoietic progenitor cells [HPCs]) expressed CD93 (Fig-
ure S1B). Linc-kithi BM cells also express CD93, while more
differentiated GR-1+ granulocytes in the BM stain negative for
CD93 (Figure S1B). Functionally,Cd93/ LSCs form significantly
fewer and smaller colonies in methylcellulose compared to con-2 Cell Reports 34, 108663, January 26, 2021trols (Figures 1C and 1D). The colony-forming capacity of LSCs
is further reduced in secondary and tertiary replatings, suggesting
thatCD93signalingpromotesself-renewal ofLT-LSCs (Figure1E).
In contrast, the clonogenic potential and cell numbers per colony
ofBL/6andCd93/ LSKsare comparable (Figures1F–1H).Over-
expression of Cd93 in BL/6 LSKs does not further increase their
clonogenic potential in vitro (Figures S1C–S1F). The reduced col-
ony-formation capacity ofCd93-deficient LSCs in vitro is indepen-
dently confirmed in knockdown experiments using Cd93-target-
ing small hairpin RNA (shRNA) (Figures 1I–1L and S2A). Extreme
limiting-dilution analysis (ELDA) reveals that knockdown of Cd93
by shRNA reduces the frequency of LSCs in limiting-dilution ex-
periments in vitroatbya factor ofR100 (Figures1Kand1L). These
data suggest that CD93 signaling is required for self-renewal of
LSCs, but not of HSCs.
CD93 signaling in LSCs promotes CML development
in vivo
To study the functional relevance of CD93 signaling in LSCs
in vivo, we transplanted BCR-ABL1-GFP transduced Cd93-pro-
ficient and deficient LSKs into nonirradiated BL/6 mice (BL/6
CML and Cd93/ CML, respectively). Transplantation of BCR-
ABL1-GFP+ Cd93/ LSKs into nonirradiated BL/6 recipient
mice does not induce CML and results in a long-term survival,
whereas Cd93-proficient BL/6 CML mice all die within 30 days
(Figures 2A and 2B). No residual BCR-ABL1-GFP+ cells are de-
tected in blood, spleen, andBMofCd93/CMLmiceby fluores-
cence-activated cell sorting (FACS) 90 days post-transplantation
(data not shown). To determine residual disease with the most
sensitive assay,we transplanted53106BMcells of surviving pri-
maryCd93/CMLmice into lethally irradiated secondary recip-
ients. All secondary recipients survive up to 90 days without any
signs of leukemia (Figure 2C). In complementary experiments, we
silenced Cd93 in FACS-sorted BL/6 LSCs by shRNA before sec-
ondary transplantation into nonirradiated BL/6 mice (Figure 2D).
shCd93 knockdown results in an up to 70% reduction of Cd93
mRNA compared to control scrambled (scr) shRNA-treated
LSCs (Figure S2B). Similar to the results obtained in primary
CML (Figures 2A and 2B), nonirradiated BL/6 mice injected with
shCd93LSCsdonot developCML, survive long-term, andharbor
no detectable disease 90 days after transplantation (Figures 2E
and 2F; data not shown).
Since nonirradiated BL/6 mice transplanted with Cd93/
CML did not develop the disease, we transplanted BCR-ABL1-
GFP-transduced Cd93/ and BL/6 LSKs into lethally irradiated
BL/6 recipient mice. Theoretically, only a few functional LSCs are
required to induce leukemia in lethally irradiated recipients
(Neering et al., 2007). Indeed, BCR-ABL1-GFP-transduced
Cd93/ LSKs are able to engraft in lethally irradiated BL/6 recip-
ients. However, the number of Cd93/ LSCs in BM is reduced
by a factor of 2 compared to BL/6 LSCs (Figure S2C).
To analyze the capacity of Cd93/ LSCs to induce CML in
immunocompetent hosts when injected at higher numbers,
FACS-purified BL/6 andCd93/ LSCs from primary lethally irra-
diated CML mice were transplanted at titrated numbers into
nonirradiated BL/6 mice, and survival was monitored (Figures
2G and 2H). All except one animal receiving BL/6 LSCs devel-
oped CML and succumbed to the disease (Figures 2G and 2H;
Figure 1. CD93 signaling regulates self-renewal of LSCs in vitro
(A and B) Representative histograms (A) and mean fluorescence intensities (MFIs) (B) for the expression of CD93 on LSCs, L-MPPs, leukemic progenitors, and
leukemic granulocytes in the BM of CML mice. Isotype is depicted in gray and CD93 staining in black. DMFI: MFI staining  MFI isotype (n = 7 mice). Repre-
sentative data from three independent experiments are shown.
(C) Myeloid colony-forming units (CFUs) per 103 plated BL/6 and Cd93/ BM LSCs.
(D) Cells per colony.
(E) Serial replating capacity of BL/6 and Cd93/ LSCs in vitro (n = 4 mice/group). One representative experiment out of two experiments is shown. For (C)–(E),
significance was determined using a Student’s t test (two-tailed).
(F) Myeloid CFUs per 103 plated BL/6 and Cd93/ BM LSKs.
(G) Cells per colony from plated LSKs (n = 6 mice/group). One representative experiments out of two independent experiments is shown.
(H) Serial replating capacity of BL/6 and Cd93/ LSKs in vitro (n = 9 mice/group). Pooled data from two independent experiments are shown. For (F)–(H),
significance was determined using a Student’s t test (two-tailed).
(I–L) Experimental setup. FACS-purified BL/6 LSCs from three different mice (n = 3 mice) were transduced with shCd93 or scrambled (scr) control RNA particles
and positively selected LSCs were plated in triplicates in methylcellulose at limiting dilution. (J) CFUs per 103 plated shCd93- or scr vector-transduced LSCs.
Significance was determined using a Student’s t test (two-tailed). (K and L) ELDA analysis. Significance was determined using a c2 test.
Data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
Article
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OPEN ACCESSdata not shown). None of the mice receiving titrated numbers of
Cd93/ LSCs developed CML, and all recipient mice survived
long-term, without signs of leukemia (data not shown). ELDA re-
vealed that CD93 deficiency substantially reduced the number of
functional LSCs capable of inducing leukemia in immunocompe-
tent mice (Figure 2H).
To determine the contribution of CD93 signaling in host cells,
BL/6 and Cd93/ LSCs were additionally transferred into
Cd93/ recipient mice. While BL/6 LSCs induced leukemia in
Cd93/ mice with similar kinetics as in BL/6 mice, Cd93/
LSCs were not able to promote leukemia development indepen-dently of the expression of CD93 on host cells (Figures S2D and
S2E). These data indicate that CD93 signaling expands LSCs
and promotes CML development in murine leukemia models.
CD93 signaling regulates self-renewal of LSCs
independently of extracellular ligand binding
CD93 has previously been described as a receptor for the com-
plement factor C1q, although these findings are controversial
(Greenlee et al., 2009; McGreal and Gasque, 2002; McGreal
et al., 2002). Heat inactivation destroys complement compo-
nents (Soltis et al., 1979). To determine whether complementCell Reports 34, 108663, January 26, 2021 3
Figure 2. CD93 signaling in LSCs promotes CML development
(A and B) Numbers of BCR-ABL1-GFP+ granulocytes/ml in blood (A) and Kaplan-Meier survival curves (B) resulting from primary transplantations of BCR-ABL1-
GFP-transduced BL/6 (BL/6 CML) orCd93/ LSKs into naive, nonirradiated BL/6 recipients (n = 10mice/group). Pooled data from two independent experiments
are shown. Significance was determined using a two-way ANOVA followed by Bonferroni post-test (A) and a log-rank test (B).
(C) 53 106 whole BM cells from primaryCd93/CMLmice 90 days after transplantation were transferred into lethally irradiated (23 6.5 Gy) secondary recipient
mice, and survival was monitored (n = 10 mice).
(D–F) Pooled FACS-purified BL/6 LSCs were transduced with shCd93 or scr control RNA lentiviral particles (n = 5 mice). shRNA-positive LSCs were selected by
culture in puromycin-containing medium for 3 days and then transplanted into naive, nonirradiated BL/6 recipients, and survival was monitored (n = 6 mice per
group). Pooled data from two independent experiments with n = 3 mice per group are shown. (D) Experimental setup. (E) Kaplan-Meier survival curves of
transplanted mice (n = 6 mice per group). Pooled data from two independent experiments with n = 3 mice per group are shown. (F) 53 106 whole BM cells from
primary shCd93 CML mice 90 days after primary transplantation were injected into lethally irradiated (2 3 6.5 Gy) recipient mice (n = 6), and survival was
monitored. Pooled data from two independent experiments with n = 3mice per group are shown. Significance for (E) and (F) was determined using a log-rank test.
(G and H) BCR-ABL1-GFP-transduced BL/6 or Cd93/ LSKs were transplanted into lethally irradiated (2 3 6.5 Gy) BL/6 recipients. After establishment of the
disease, BL/6 or Cd93/ LSCs were FACS purified and injected at limiting dilution into naive, nonirradiated BL/6 mice, and survival was monitored (n = 3 mice/
dilution). (H) ELDA analysis. #, LSCs needed to induce CML in immunocompetent hosts. INF, infinity. One representative experiment out of two independent
experiments is shown. Significance was determined by c2 test.
Data are represented as mean ± SD. *p < 0.05; ***p < 0.001; ****p < 0.0001.
Article
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OPEN ACCESSfactors, including C1q, trigger CD93 signaling in CML LSCs, we
performed colony assays of Cd93-proficient and deficient
LSCs in the presence of heat-inactivated (HI; no complement)
and non-heat-inactivated (NHI; complement) fetal calf serum
(FCS). BL/6 LSCs generate significantly more colonies than
Cd93/ LSCs independent of complement (Figure S2F).
To studywhether CD93 signaling in LSCs relies on ligand bind-
ing to the extracellular domain of CD93, we generated retroviral4 Cell Reports 34, 108663, January 26, 2021vectors expressing either the complete murine Cd93 (mCd93) or
a mutant with extracellular domain deletion of CD93 (mCd93intra;
Figures 3A and S3A–S3F). FACS analysis revealed that CD93
protein was detectable on mCd93-transduced Cd93/ LSCs
at a similar level as on empty vector (mock)-transduced BL/6
LSCs (Figure 3C). Interestingly, transduction of Cd93/ LSCs
with both mCD93 and mCd93intra restored colony formation of
Cd93/ LSCs in vitro (Figures 3D and 3E). These data indicate
Figure 3. CD93 signaling regulates self-renewal of LSCs independent of extracellular ligand binding
(A–E) FACS-purified Cd93/ CFP+ LSCs were transduced with an empty-GFP (mock)-, mCd93-GFP-, or mCd93intra-GFP-expressing retroviral particles in
triplicate. GFP+ LSCs were plated in methylcellulose in triplicate, and colony formation was assessed. (A) Domain structure of mCd93 and mCd93intra. (B)
Experimental setup. (C) CD93 expression on CFP+ GFP+ LSCs (gray, Cd93/ LSCs; black, BL/6 LSC: blue, mCd93 LSCs). (D) CFUs per 103 plated CFP+ GFP+
LSCs (n = 3 in triplicate/group). Significance was determined using a one-way ANOVA followed by Dunnett’s post-test (versus Cd93/ mock). (E) Colony
formation of FACS-purifiedCd93/CFP+ LSCs transduced with mock,mCd93, ormCd93intra retrovirus. One representative experiment out of two independent
experiments is shown. Significance was determined using a one-way ANOVA followed by Dunnett’s post-test (versus Cd93/ mock).
(F–I) The BCR-ABL-1-positive cell line K562 and the BCR-ABL-1-negative cell lines EL-4 and STR-4 were transfected with the mammalian expression plasmid
pAcGFP1-N1-mCd93 encoding for AcGFP1-N1-mCd93 in triplicate. 48 h later, cells were analyzed for the subcellular localization of CD93. (F) Subcellular
localization of CD93 in K562 cells analyzed by ImageStream. Two representative images of non-nuclear and nuclear CD93-GFP expression are shown. A
minimum 1,200 GFP+ cells pre-sample were analyzed. (G) Percentage of nuclear and non-nuclear CD93-GFP localization analyzed by ImageStream. One
representative experiment out of two independent experiments is shown. Significance was determined using a one-way ANOVA followed by Dunnett’s post-test
(versus K562). (H) Nuclear and cytosolic CD93-GFP determined bywestern blot. (I) Subcellular localization of CD93 in K562 cells treated with nilotinib (NIL; 70 mM)
or vehicle for 72 h in triplicate. One representative experiment out of two independent experiments performed in triplicate is shown. Significance was determined
using a Student’s t test (two tailed).
(J) Subcellular localization of CD93 in K562 cells treated with PKC 20-28 (PKC; 50 mM) or vehicle for 72 h. One representative out of two independent experiments
performed in triplicate is shown. Significance was determined using a Student’s t test.
Data are represented as mean ± SD. **p < 0.01; ***p < 0.001.
Article
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LSCs independent of an extracellular ligand-receptor
interaction.
The ICD of CD93 contains a nuclear localization signal that is
thought to regulate gene transcription (Cokol et al., 2000). To
investigate the subcellular localization of CD93 in CML, we
cloned mCd93 to the N terminus of a mammalian expression
plasmid, AcGFP1 (pAcGFP1-N1-mCd93), which leads to the
expression of mCD93 protein fused to GFP (Figure S3G).pAcGFP1-N1-mCd93 was introduced into K562 CML cells
(Chen, 1985), and the localization of the GFP-CD93 fusion pro-
tein was assessed by ImageStream (Figure 3F). The CD93-
GFP fusion protein was detected at the cell membrane of all cells
expressing pAcGFP1-N1-mCd93 (non-nuclear). Approximately
25% of these cells also expressed the fusion protein in the nu-
cleus (Figures 3F and 3G). Cells transfected with pAcGFP1-
N1-empty did not show a nuclear CD93-GFP signal (data not
shown). These results are confirmed independently using aCell Reports 34, 108663, January 26, 2021 5
(legend on next page)
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(pLVX-AcGFP1-N1-mCd93) or AcGFP1-N1-empty (Figures
S3H and S3I). To further confirm the nuclear localization of
CD93, nuclear and cytosolic extracts of K562 cells transduced
with AcGFP1-N1-mCd93 (CD93-GFP) or pAcGFP1-N1-empty
(eGFP) were analyzed by western blot for the expression of
GFP. CD93-GFP is detected in the cytosolic and in nuclear frac-
tion of the cell extract (Figure 3H).
To investigate whether the subcellular distribution of CD93 is
dependent on the expression of the BCR-ABL1 oncogene, we
assessed the localization of CD93-GFP in BCR-ABL1-negative
CD93-expressing EL-4 lymphoma (Gorer, 1950) and STR-4
endothelial BM cells (Aizawa et al., 1991) after transfection with
pAcGFP1-N1-mCd93. In contrast to BCR-ABL1-expressing
K562 CML cells, the CD93-GFP fusion protein was detected at
the cell membrane, but not in the nucleus of EL-4 and STR-4
cells (Figure 3G). Based on these findings, we hypothesized
that the expression of nuclear CD93 is dependent on BCR-
ABL1 activity. To analyze this, we inhibited BCR-ABL1 activity
in K562 CML cells using half maximal inhibitory concentrations
(IC50) of the TKI nilotinib. Pharmacological blockade of BCR-
ABL1 activity significantly reduced the nuclear localization of
CD93-GFP compared to vehicle-treated K562 cells (Figure 3I).
These findings were confirmed using an intracellular antibody
staining combined with ImageStream analysis (Figures S4A
and S4B). In addition, we overexpressed mCd93 in BL/6 LSCs.
Overexpression of CD93 in LSCs did not result in increased clo-
nogenic potential and did not affect their responsiveness to nilo-
tinib treatment (Figures S4C–S4F).
In monocytes, the generation of CD93 ICD has been previ-
ously shown to depend on protein kinase C (PKC) activity to pro-
mote their phagocytic activity (Bohlson et al., 2005a; Greenlee
et al., 2009). Thus, we addressed whether a pharmacological in-
hibitor of PKC-a/b activity affects the subcellular localization of
CD93-GFP in CML cells by ImageStream. Incubation of K562
cells with PKC 20–28 at an IC50 concentration of 50 mM reduced
40% of the subcellular localization of CD93 compared to
vehicle-treated control cells (Figure 3J). Overall, these results
demonstrate that nuclear localization of CD93 depends on
PKC-a/b- and BCR-ABL1.
CD93 signaling triggers stem-cell-maintenance- and
cell proliferation-promoting signaling pathways in CML
LSCs
The nuclear localization of the ICD of CD93 in CML suggests that
CD93 might act as a transcription factor and regulate gene
expression. Thus, we performed RNA-seq analysis of BL/6 and
Cd93/ LSCs 48 h after transfer into nonirradiated secondaryFigure 4. CD93 triggers stemness- and proliferation-promoting genes
(A) Experimental setup. BCR-ABL1-GFP-transduced BL/6 or Cd93/ LSKs we
disease, BL/6 LSCs or Cd93/ LSCs were purified, and 53 104 LSCs were injec
was analyzed by RNA sequencing (RNA-seq).
(B) PCA of BL/6 and Cd93/ LSKs (n = 2 mice/group) as well as BL/6 and Cd93
(C) Venn diagram showing up- and downregulated genes in Cd93/ versus BL/
(D) GO analysis (BL/6 versus Cd93/ LSCs). A GO enrichment score of R3 indi
(E–J) GSEA of significantly enriched genes in BL/6 versus Cd93/ LSCs.
(K) Heatmap of 70 differentially expressed genes promoting stem cell maintenanBL/6 recipients (Figure 4A). To investigate whether different
gene expression profiles already exist in naive LSKs, we also
included Cd93-proficient and deficient LSKs in the analysis. All
samples had a similar number of reads (Figure S4G). BL/6 and
Cd93/ HSCs closely clustered together in the principal-
component analysis (PCA), and only 170 genes were differently
expressed. BL/6 and Cd93/ LSCs clearly separated from
LSKs based on the expression of the BCR-ABL1 oncogene (prin-
cipal component 1 [PC1]). Importantly, BL/6 and Cd93/ LSCs
were very different from each other (Figure 4B, PC2 and PC3), as
reflected by differential expression of 1,120 genes in Cd93/
versus BL/6 LSCs (Figure 4C; Table S1). Of note, Cd93/
LSKs shared only two differentially expressed genes with
Cd93/ LSCs (Figures 4C and S5A).
Gene Ontology (GO) analysis assigned the 1,120 differently
expressed genes in Cd93/ LSCs mainly into 14 different GO
categories (Figure 4D). Gene set enrichment analysis (GSEA)
revealed a significant downregulation of genes involved in pro-
moting stem cell maintenance and myeloid differentiation, cell
proliferation and survival, response to cytokine signaling, and
gene expression (Figures 4E–4K). RNA-seq results were inde-
pendently confirmed by qRT-PCR for a set of selected genes
(Figure S5I). In contrast, GSEA of naive BL/6 and Cd93/
HSCs did not reveal a dysregulation in these pathways (Figures
S5C–S5H; Table S1). In summary, our data suggest that CD93
signaling triggers a defined stemness- and proliferation-associ-
ated gene expression signature in CML LSCs, but not in normal
HSCs.
CD93 signaling regulates gene transcription in CML
LSCs via Scyl1
To further determine the mechanism how CD93 affects gene
expression in CML LSCs, we performed an in silico pathway
analysis for proteins with a predicted physical interaction with
CD93. The analysis identified six functional interaction partners
for CD93. Among these six interaction partners, we identified
one protein, SCYL1, with a reported role as a regulator of gene
transcription (Figure 5A) (Burman et al., 2008). SCYL1 alias
P105 was shown to interact directly with the highly charged
juxta-membrane domain of the cytoplasmic tail of CD93 using
a yeast-two-hybrid screen (Bohlson et al., 2005b). Scyl1 was
comparably expressed inBL/6 LSKs andBL/6 LSCs (FigureS5J).
However, Scyl1 expression was strongly reduced in Cd93/
LSCs compared to BL/6 LSCs (Figure 5B). SCYL1 activated tran-
scription of the telomerase reverse transcriptase (Tert) and DNA
polymerase beta (Polb), two DNA polymerases that are overex-
pressed in many different cancer types with a reported role in
the regulation of cell immortalization and tumorigenesis (Devillein CML LSCs
re transplanted into lethally irradiated BL/6 recipients. After establishment of
ted into naive BL/6 mice. 48 h later, LSCs were isolated, and gene expression
/ LSCs (n = 3 mice per group).
6 LSCs compared to Cd93/ versus BL/6 LSKs.
cates significant changes in gene expression.
ce and myeloid differentiation.
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Figure 5. CD93 signaling triggers regulation of gene transcription in via SCYL1 in CML LSCs
(A) In silico analysis of predicted CD93 interaction partners using the GeneMANIA database (http://www.genemania.org/) (Warde-Farley et al., 2010).
(B) Scyl1, Tert, and Polb mRNA expression in CD93/ and BL/6 LSKs and LSCs (n = 3 mice/group). Significance was determined using a Student’s t test.
(C) Pooled FACS-purified BL/6 and Cd93/ LSCs (n = 5 mice/group) were transduced with esiScyl1 or scr control esiRNA particles in triplicate, and gene
expression was determined 48 h later. mRNA expression of Cd93, Scyl1, Polb, Tert, CCnd2, Id2,Myb, and Rela 48 after gene silencing of Scyl1 by esiRNA. KD,
knockdown efficiency (esiRNA versus scr).
(D) Colony formation. BL/6 andCd93/ LSCs were transduced esiScyl1 or scr control esiRNA particles as described in (C) followed by plating in methylcellulose
in triplicate. Colony formation was assessed 7 days later. Significance was determined using a one-way ANOVA followed by Tukey’s post-test.
(E–G) Pooled BCR-ABL1 CFP+ BL/6 and Cd93/ LSCs (n = 5 mice/group) were transduced with a retrovirus expressing empty-GFP or Scyl1-GFP. 2 days later,
CFP+GFP+ LSCs were FACS purified, 103 cells were plated in methylcellulose in triplicate, and 104 cells were used for qRT-PCR analysis of Scyl1. Colony
formation was assessed 7 days later. (E) Scyl1, CD93, Tert, and PolB mRNA expression, (F) colony formation, and (G) colony size of BL/6 and Cd93/ LSCs
expressing empty-GFP or Scyl1-GFP. Significance was determined using a one-way ANOVA followed by Tukey’s post-test.
Data are represented as mean ± SD. **p < 0.01; ***p < 0.001.
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OPEN ACCESSet al., 2009; Zhao et al., 2005). Polb and Tert expression was
significantly reduced in Cd93/ LSCs (Figure 5B). To analyze
the role of Scyl1 in CML LSCs, we silenced Scyl1 in Cd93/
and BL/6 LSCs by endoribonuclease-prepared siRNA (esiRNA).
esiScyl1 knockdown resulted in70% reduction of Scyl1mRNA
in BL/6 LSCs compared to scr esiRNA-treated LSCs (Figure 5C).
Silencing of Scyl1 in BL/6 LSCs reduced the expression of the
target genes Polb and Tert and selected genes related to self-
renewal and proliferation (Figure 5C). Importantly, silencing
Scyl1 significantly reduced colony formation of BL/6, but not
Cd93/, LSCs in vitro (Figure 5D). Vice versa, overexpression
of Scyl1 in Cd93/ LSCs increased mRNA expression of Tert
and PolB and restored the clonogenic and differentiation poten-
tial of Cd93/ LSCs to levels of empty-vector-transduced BL/6
LSCs (Figures 5E–5G). In contrast, overexpression of Scyl1 in
BL/6 LSCs did not affect Tert and PolB mRNA expression and
their capacity to form colonies in vitro (Figure 5F, G). Overall,
these findings indicate that the ICD of CD93 regulates gene tran-
scription via Scyl1 and its downstream genes, Polb and Tert, in
CML LSCs.
CD93 signaling regulates proliferation of CML LSCs
Next, we analyzed the cellular processes by which CD93
signaling affects LSC function in more detail. Because CD93 is
thought to be involved in cell adhesion and migration (Zhang
et al., 2005), we first assessed the homing capacity of LSCs
into the BM. Transplanted Cd93/ and BL/6 LSCs similarly
homed to the BM of lethally irradiated as well as nonirradiatedFigure 6. CD93 signaling induces proliferation of LSCs and is blocked
(A) Experimental setup. FACS-purified BL/6 and Cd93/ LSCs from lethally irradi
as well as lethally irradiated BL/6 secondary recipient mice (n = 4 mice/group).
(B) Representative FACS plots of BCR-ABL1-GFP+ BL/6 and Cd93/ LSCs in the
mice/group).
(C) Frequencies of BCR-ABL1-GFP+ BL/6 and Cd93/ LSCs (n = 4 mice/group)
(D) BCR-ABL1-GFP+ CFU capacity of total Lin cells (n = 4 mice/group). Signific
experiment out of two independent experiments is shown.
(E) Experimental setup. FACS-purified BL/6 andCd93/ LSCs from lethally irradi
(n = 5 mice/group). After 24 h, animals were treated intraperitoneally (i.p.) with 1
(F) Frequency of BrdU+ LSCs (n = 5 mice/group). Significance was determined u
(G) LSC viability as determined by viability dye staining (n = 5mice/group). Significa
experiment out of two independent experiments is shown.
(H) LSCs derived fromBL/6 andCd93/CMLmice (n = 3mice/group) were cultur
Colony formation was assessed 7 days later. Significance was determined using
independent experiments is shown.
(I) LSCs derived from BL/6 and Cd93/ CML mice (n = 3 mice/group) were cultu
was determined 48 h later.
(J) K562CML cells were transfectedwith themammalian expression plasmid pAcG
or absence of 1 mMMCP. After 72 h, cells were analyzed for the subcellular locali
are shown. Significance was determined using a Student’s t test.
(K and L) Numbers of BCR-ABL1-GFP+ granulocytes/ml in blood (K) and Kaplan-M
GFP-transduced BL/6 LSKs into naive, nonirradiated BL/6 recipients. Starting a
(10 mg/kg; n = 10mice/group) for a period of 20 days. Significance was determine
Pooled data from independent experiments are shown.
(M) Summary of the RNA-seq results. Volcano plot representation of differentially e
Blue and red points mark the genes with significantly increased or decreased exp
mice (false discovery rate [FDR] < 0.05). The x axis shows fold changes in gene e
expressed. Only genes with a fold change >10 and <10 are shown.
(N) GO analysis (MCP versus vehicle). A GO enrichment score of R3 indicates s
(O–Q) GSEA of LSCs derived from CML mice treated with vehicle or MCP (n = 3
Data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.
10 Cell Reports 34, 108663, January 26, 2021BL/6 recipients (Figures 6A–6C). To confirm a similar frequency
of functional LSCs in the BM 14 h after transplantation, total
Lin cells were plated in methylcellulose, and BCR-ABL1-GFP+
colonies were assessed 7 days later. Lin cells from mice
receiving Cd93/ and BL/6 LSCs formed similar numbers of
BCR-ABL1-GFP+ colonies (Figure 6D). These results indicate
that CD93 signaling does not affect homing of LSCs in vivo.
Next, we assessed whether CD93 signaling affects prolifera-
tion and cell survival of LSCs. We injected Cd93-proficient and
deficient LSCs into nonirradiated BL/6 mice (Figure 6E). Bromo-
deoxyuridine (BrdU)+ incorporation is 40% lower in Cd93/
LSCs than in BL/6 LSCs, indicating a reduced proliferation of
LSCs in the absence of CD93 (Figure 6F). Viability of BL/6 and
Cd93/ LSCs was comparable (Figure 6G). Overall, and in line
with the data obtained in the gene enrichment analysis, these
data suggest that Cd93/ signaling promotes proliferation but
does not affect apoptosis or homing of LSCs in vivo.
MCP blocks CD93 signaling and reduces LSC function
in vitro.
To discover compounds that potentially block CD93 signaling,
we performed a compound screen using the US Food and
Drug Administration (FDA)-approved drug library V2 (Lago
et al., 2019) (Table S2). Cd93-proficient and deficient LSCs
were incubated overnight with 1 mM of the respective com-
pounds, followed by plating in methylcellulose. Out of the 240
compounds tested, 10 compounds blocked CD93 signaling (Ta-
ble S2). One interesting candidate that we identified in theby metoclopramide (MCP) treatment
ated (23 6.5 Gy) primary CMLmice were injected intravenously (i.v.) into naive
BM of naive BL/6 secondary recipients 14 h after transplantation mice (n = 4
. Significance was determined using a Student’s t test.
ance was determined using a Student’s t test. For (A)–(D), one representative
ated primary CMLmice were transplanted into naive BL/6 secondary recipients
mg BrdU and sacrificed 14 h later.
sing a Student’s t test.
ncewas determined using a Student’s t test. For (F) and (G), one representative
ed overnight in duplicate with 1 mMMCP followed by plating in methylcellulose.
a one-way ANOVA followed by Tukey’s post-test. One representative out two
red in duplicate with 1 mM MCP, and mRNA expression of the indicated genes
FP1-N1-mCd93 encoding for AcGFP1-N1-mCd93 in triplicate in the presence
zation of CD93 by ImageStream. Pooled data of two independent experiments
eier survival curves (L) resulting from primary transplantations of BCR-ABL1-
t the day of transplantation, mice were treated p.o. with vehicle (Veh) or MCP
d by two-way ANOVA followed by Bonferroni post-test (K) and log-rank test (L).
xpressed genes in LSCs derived fromMCP- versus vehicle-treated CMLmice.
ression, respectively, in LSCs derived from MCP- versus vehicle-treated CML





OPEN ACCESScompound screen is the anti-emetic agent MCP. MCP treatment
reduced colony formation of BL/6 LSCs to comparable levels as
Cd93/ LSCs without further affecting colony formation of
Cd93/ LSCs (Figure 6H). Comparable to blockade of CD93
signaling (Figure 4), MCP treatment reduced the expression of
stem-cell-related genes as well as Scyl1, Polb, and Tert in BL/
6 LSCs (Figure 6I). Overexpression of CD93 did not rescue the
effect of MCP treatment on colony-formation capacity, indi-
cating that the observed effect is dependent not on total CD93
expression but on the nuclear localization of the cleaved intracel-
lular part of CD93 (Figure S6A).
To investigate whether MCP treatment directly affects CD93
signaling through modulation of the subcellular localization of
CD93 in CML, we cultured CD93-GFP-transfected K562 cells
in the presence or absence of 1 mM of MCP. CD93-GFP nuclear
localization in MCP-treated K562 cells was significantly reduced
compared to vehicle-treated cells (Figure 6J). Overall, these data
suggest that MCP treatment reduces the function of CML LSCs
through modulation of CD93 signaling.
MCP treatment prolongs survival of CML mice through
downregulation of stem-cell-maintenance- and cell-
proliferation-promoting signaling pathways in CML
LSCs
To validate our findings in vivo, BL/6micewere treated once daily
with vehicle or 10 mg/kg MCP orally (p.o.) (Shalaby et al., 2013)
starting at the day of leukemia transplantation for a period of
20 days. MCP treatment significantly delayed leukemia develop-
ment and prolonged survival compared to the vehicle-treated
group independent of the route of administration (Figures 6K
and 6L).
To determine which signaling cascades are altered in LSCs
upon MCP treatment, we performed RNA-seq analysis of LSCs
isolated from the BM of CML mice that were previously treated
with vehicle or MCP for 3 days starting at day 13 after CML in-
duction. MCP treatment significantly reduced the leukemia
load, as indicated by a decrease in BCR-ABL1-GFP+ granulo-
cyte numbers in peripheral blood and spleen weight as well as
lower numbers of LSCs in the BM (Figures S6B–S6D).
LSCs derived from CML mice treated with MCP clearly sepa-
rated from control LSCs (Figure S6E). RNA-seq analysis identified
105 genes that are differentially expressed between the two treat-
ment conditions (Figure 6M; Table S1). Similar to Cd93/ LSCs
(Figure 4C), the vast majority of genes in LSCs fromMCP-treated
CML mice were downregulated compared to controls. GO anal-
ysis assigned the 105 differently expressed genes mainly into 11
different GO categories (Figure 6N). GSEA revealed a significant
downregulation of genes involved in promoting stem cell mainte-
nance and myeloid differentiation, cell proliferation and survival,
response to cytokine signaling, and gene expression (Figures
6O–6Q and S6F–S6H). These data suggest that MCP treatment,
similar to blockade of CD93 signaling, reduces the expression
genes associated with stemness and proliferation in LSCs.
CD93 is expressed on the surface and in the nucleus of
primary human CML stem/progenitor cells
To determine the relevance of our findings for human CML, we
analyzed mRNA expression of CD93 and its downstream target,SCYL1, in BM, CD34+CD38+ leukemia progenitors, and
CD34+CD38 LSCs of chronic-phase CML patients using two
publicly available microarray datasets (GSE4170 and
GSE43754) (Gerber et al., 2013; Radich et al., 2006). We identi-
fied CD93 and SCYL1 expression in chronic-phase CML BM
and CML stem/progenitor cells, but not in CD34+ stem/progen-
itor cells from healthy donors (Figures 7A and 7B).
Immunohistochemistry (IHC) of BM sections of CML patients
revealed CD93 protein expression on CD34+ LSCs and BM
vascular ECs (Table S3; Figures 7C and 7D). Similarly, CD93
was detected on BM LinCD34+ and LinCD34+CD38 CML
stem/progenitor cells by FACS (Figures 7E and S6I). In line
with previous findings (Iwasaki et al., 2015; Kinstrie et al.,
2020; Saito et al., 2010), CD93 expression cannot be detected
on the surface of stem and progenitor cells from healthy donor
BM by FACS (Figure 7F).
Next, we addressed the subcellular distribution of CD93 in pri-
mary CD34+ CML stem/progenitor cells by ImageStream anal-
ysis. CD93 was detectable in the nucleus of primary CD34+
CML stem/progenitor cells (Figure 7G). In line with our findings
derived in K562 CML cells, nilotinib treatment significantly
reduced the frequency of cells expressing CD93 in the nucleus.
In contrast, total CD93 expression was not affected by nilotinib
treatment (Figure S6J). Overall, these data suggest that the local-
ization of the cleaved intracellular part of CD93 is dependent of
BCR-ABL1 activity (Figure 7H).
CD93 signaling regulates the colony-formation capacity
of human CML stem/progenitor cells in vitro
To analyze the role of CD93 signaling, we treated FACS-purified
LinCD34+ CML stem/progenitor cells with CD93-targeting
(siCD93) or control small interfering RNA (siRNA) (siCTRL)
followed by plating in methylcellulose and gene expression anal-
ysis using qRT-PCR (Figures 7I–7L). Silencing of CD93 signifi-
cantly reduced the expression of stem cell self-renewal- (ID2,
MYB, PAK2, and REL) and proliferation-promoting genes (CK1,
CDK4, and CCND2), as well as genes associated with genome
maintenance (TERT and POLB) (Figure 7J). These transcriptomic
changes were functionally confirmed by a significantly reduced
colony-formation capacity in the absence of CD93 signaling
(Figure 7K). In contrast, CD93 signaling did not affect colony for-
mation of normal BM stem/progenitor cells (Figure 7L). To deter-
mine the effect of MCP treatment on human CML, we incubated
FACS-purified CD34+ BM CML stem/progenitor cells with two
different concentrations ofMCP followed by plating inmethylcel-
lulose. The plasma concentrations reached in humans treated
with MCP is between 0.1 and 0.2 mM (Magueur et al., 1991).
Comparable to blockade of CD93 signaling (Figure 7J), MCP
treatment reduced the expression of SCYL1, POLB, and TERT
in CML stem/progenitor cells (Figure 7M). In addition, colony for-
mation in semi-solid cultures was significantly impaired by MCP
treatment. This effect is maintained in subsequent replatings,
even in the absence of MCP (Figure 7N). Importantly, the clono-
genic potential of hematopoietic stem/progenitor cells from
healthy donor BM was not affected by the treatment (Figures
S6K–S6M).
We next investigated whether a treatment combination with
MCP and nilotinib results in further reduction in colony formationCell Reports 34, 108663, January 26, 2021 11
Figure 7. CD93 regulates colony-forming capacity of CD34+ BM stem/progenitor cells from CML patients in vitro
(A) A publicly available microarray dataset (GSE4170) that assessed gene expression profiles in CML was analyzed for CD93 and SCYL1 using the Gene
Expression Omnibus GEO2R tool. Expression values of patients in chronic-phase CML (n = 42; green bars) and CD34+ stem/progenitor cells from healthy donor
BM (n = 5; black bars) are shown.
(B) Expression of CD93 and SCYL1 mRNA in CD34+CD38+ leukemia progenitor cells (Prog.) and CD34+CD38 LSCs from chronic-phase CML patients
(GSE43754, n = 5 patients/group).
(C and D) CD93+CD34+ stem/progenitor cells in the BM of healthy donors (n = 3) and untreated CML patients (n = 4) were determined by immunohistochemistry
(IHC) and cell morphology. (C) Representative IHC image for CD34 and CD93 in BM of CML (n = 4 CML patients). Slides were stained with a rabbit anti-human
CD93 antibody, and staining was visualized with a 3,3’-diaminobenzidine (DAB) detection kit. Slides were subsequently counterstained and visualized with a
mouse anti-human CD34 antibody and a red detection kit, respectively, followed by a counterstain with hematoxylin. CD93 is stained in brown and CD34 in red.
Scale bar, 20 mm. Black arrows indicate CD93+CD34+ double-positive stem/progenitor cells. (D) Percentage of CD93-expressing CD34+ cells in CML and normal
healthy donor BM (H) as analyzed by IHC. 145–328 CD34+ BM cells were analyzed per trephine biopsy. Significance was determined using a Student’s t test (two
tailed).
(E) Representative FACS histograms (left panel) and the MFI (right panel) of CD93 expression versus isotype control on LinCD34+ BM cells from CML patients.
DMFI: MFI staining  MFI isotype.
(F) Histograms of CD93 expression on CD34+ BM stem/progenitor cells from healthy donors (H4–H6) as analyzed by FACS. Black lines, CD93 staining; gray lines,
isotype controls.
(G) Subcellular localization of CD93 ICD in LinCD34+ CML stem/progenitor cells (CML 1 and 8–10). A minimum 5 3 103 cells pre-sample were analyzed. K562
and STR-4 cells served as positive and negative controls for nuclear CD93 expression, respectively. Numbers indicate patient IDs (Table S3).
(H) Subcellular localization of ICD of CD93 in LinCD34+ CML stem/progenitor cells (CML 1, 8, 10, and 11) treated with nilotinib (NIL; 5 mM) or vehicle for 24 h. A
minimum of 103 cells per sample were analyzed. Numbers indicate patient IDs (Table S3). Significance was determined by paired Student’s t test (two tailed).
(I–L) LinCD34+ BM stem/progenitor cells from CML patients 8–10 (Table S3) were treated with siCD93 RNA (siCD93) or control siRNA (siCTRL) for 48 h in
triplicate, followed by plating in methylcellulose or RNA isolation. (I) Experimental setup. (J) Heatmap for the expression of CD93 and selected genes involved in
self-renewal and cell proliferation in siCTRL versus siCD93 cells. (K) Colony formation per 2,000 plated CD34+ BM stem/progenitor cells. Significance was
determined using a Student’s t test (two tailed). (L) Colony formation of 1,000 plated normal CD34+ BM stem/progenitor cells (H1 and H2) after silencing of CD93
by siRNA. Significance was determined using a Student’s t test.
(M) CD34+ BM CML stem/progenitor cells (CML 8, 10, and 11) were treated 1 mMor vehicle overnight in triplicate followed by mRNA isolation. Heatmap of CD93,
SCYL1, POLB, and TERT expression.
(N) CD34+ BM CML stem/progenitor cells (CML 8, 10, and 11) were treated with titrated concentrations of MCP or vehicle overnight in triplicate, followed by
plating in methylcellulose. Colony formation of 2,000 plated cells for primary platings is shown. For secondary platings, 23 104 cells isolated from primary colony
assays were replated in methylcellulose in the absence of the compound.
(O) CD34+ BMCML stem/progenitor cells (CML 8, 10 and 11) were treated withMCP (1 mM) and/or nilotinib (NIL; 5 mM) overnight in triplicate, followed by plating in
methylcellulose. Colony formation of 2,000 plated cells for primary platings is shown. Significance was determined using a one-way ANOVA followed by Tukey’s
post-test.
Data are represented as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001.






OPEN ACCESSof CML stem/progenitor cells. We incubated FACS-purified
CD34+ BM CML stem/progenitor cells with 5 mM nilotinib and
1 mM MCP alone or in combination followed by plating in meth-
ylcellulose. The clonogenic potential in semi-solid cultures was
significantly impaired by co-treatment compared to single treat-
ments (Figure 7O). In summary, CD93 signaling expands human
LSCs, a process that is efficiently blocked by MCP treatment.
DISCUSSION
The cancer stem cell (CSC) model suggests that leukemia may
only be eradicated long-term by targeting disease-initiating
and disease-maintaining LSCs (Holyoake and Vetrie, 2017;
Riether et al., 2015a). LSCs frequently activate self-renewal
and proliferation pathways to resist cytotoxic drugs and propa-
gate the disease. These self-renewal pathways developed dur-
ing evolution to maintain normal HSCs, the cell of origin for
CML LSCs (Horne and Copland, 2017; Huntly and Gilliland,
2005). The selective elimination of LSCs requires the exploitation
and targeting of unique signaling pathways that promote the
self-renewal of LSCs, but not normal HSCs.
In the present study, we describe CD93 as an important regu-
lator of self-renewal and proliferation of human and murine LSCs
in CML. CD93 is expressed on many different cells, including
ECs, plasma cells, B cell precursor cells, and hematopoietic cells
(Dean et al., 2000, 2001; Løvik et al., 2000; McKearn et al., 1985;
Nepomuceno et al., 1997). Interestingly, CD93 expression has
been documented on CML LSCs and non-quiescent human
MLL-rearranged AML LSCs, but not humans HSCs (Herrmann
et al., 2020; Iwasaki et al., 2015; Kinstrie et al., 2020). In line
with these findings, we document CD93 expression on all CML
LSC subsets. CD93 deficiency in LSCs resulted in a severe
impairment of proliferation and self-renewal of LSCs. As a
consequence, CD93-deficient LSCs did not propagate the
disease in immune-competent recipients. In contrast, although
murine HSCs express CD93, self-renewal of HSCs was indepen-
dent of CD93. Cd93/ LSCs have a silenced gene expression
signature, particularly for genes involved in cell proliferation
and division as well as stem cell maintenance andmyeloid differ-
entiation. Out of the 1,120 genes differentially expressed
between BL/6 and Cd93/ LSCs, 1,108 genes were downregu-
lated. Similarly, knockdown of CD93 in human CML stem/pro-
genitor cells reduced the expression of selected genes involved
in stem cell self-renewal (ID2,MYB, PAK2,MEIS1, and REL) and
proliferation (CK1, CDK4, and CCND2), confirming our results
obtained in the murine CML model. These transcriptional
changes resulted in a reduced colony-formation capacity
in vitro, suggesting a similar regulation of CML stem/progenitor
cells by CD93 in humans.
It is well documented that LSC self-renewal pathways are
regulated by cell-autonomous signaling through interactions be-
tween LSCs and cells of the BMmicroenvironment or via altered
intracellular signaling cascades mediated by the expression of
the oncogene itself (Holyoake and Vetrie, 2017; Riether et al.,
2015a). We demonstrate that LSCs regulate their function by
promoting intracellular CD93 signaling via the ICD of CD93 inde-
pendent of an extracellular ligand-receptor interaction. The for-
mation of the CD93 ICD in leukemia cells was dependent onPKC activity. Similarly, in monocytes, the generation of CD93
ICD depends on PKC activity to promote their phagocytic activ-
ity (Bohlson et al., 2005a; Greenlee et al., 2009).
The ICD of CD93 contains a nuclear localization signal that is
thought to regulate gene expression by acting as a transcription
factor (Cokol et al., 2000). Genes involved in the regulation of
gene expression were significantly silenced in LSCs in the
absence of CD93 signaling. Our data suggest that signaling via
the ICD of CD93 regulates gene expression in CML LSCs
through interaction with the transcriptional regulator SCYL1
(Burman et al., 2008; Kato et al., 2002; Liu et al., 2000). SCYL1
has been previously identified to bind the ICD of CD93 through
interaction with the juxta membrane domain of CD93 (Bohlson
et al., 2005b). This signaling pathway is comparable to several
other surface receptors regulating self-renewal in CML LSCs
such as Notch, CD44, and others where the ICD fragment relo-
cates to the nucleus and regulates gene transcription (Medina
and Dotti, 2003; Okamoto et al., 2001; Schroeter et al., 1998).
The ICDs of Notch1 and CD44 act as a co-transcription factors
to trigger their own production and potentiate Notch1- and
CD44 signaling (Okamoto et al., 2001; Sjöqvist et al., 2014). Simi-
larly, CD93 deficiency resulted in a downregulation of SCYL1
suggesting a similar positive feedback loop for CD93 signaling.
Similar to CD93, the nuclear localization of ICD of Notch1 and
CD44 proteins is regulated by the activation of PKCs (Okamoto
et al., 1999; Sjöqvist et al., 2014)
The promoters of both TERT and POLB belong to the promoter
of TATA- orCAAT-lessGC-rich genes, suggesting that some tran-
scription factorsmight be involved in the transcriptional regulation
of both polymerases (Kanamoto et al., 2004;Wick et al., 1999). As
an example, SCYL1 binds to the promoters of DNA polymerases
TERT and POLB, resulting in their transcription and activation
(Deville et al., 2009; Zhao et al., 2005). TERT and POLB are active
in normal stem cells and most cancer cells, including CSCs, but
not in more differentiated cells (Deville et al., 2009; Zhao et al.,
2005). POLB expression and activity are significantly higher in pe-
ripheral blood mononuclear cells (PBMCs) of CML patients
compared to healthy donors (Canitrot et al., 2006). Similarly, telo-
merase expression and activity has been shown to increase in un-
fractionated BM cells of patients with CML during disease pro-
gression (Ohyashiki et al., 1997; Tatematsu et al., 1996;
Verstovsek et al., 2003).
Our data indicate that silencing of CD93 or SCYL1 genes in
LSCs reduces the expression of TERT and POLB in CML
LSCs, resulting in the loss of proliferation and stem cell function.
In line with these findings, studies on glioblastoma, neuroblas-
toma, breast cancer, prostate cancer, and pancreatic cancer
documented increased telomerase activity in CSCs compared
to non-CSCs. Inhibition of telomerase activity reduced self-
renewal of CSCs, documenting a role of TERT in the regulation
of stemness in CSCs (Castelo-Branco et al., 2011; Marian
et al., 2010b, 2010a; Shay and Wright, 2010).
Due to its broad expression on different cell types, including
ECs, targeting CD93 with antibodies, antibody conjugates, or
chimeric antigen receptor (CAR)-T cells is difficult. However,
the fact that the ICD of CD93 regulates gene expression and
self-renewal exclusively in BCR-ABL1-transformed cells offers
a selective targeting of this pathway in CML. We thereforeCell Reports 34, 108663, January 26, 2021 13
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OPEN ACCESSperformed a compound screen using the FDA-approved drug li-
brary and identified 10 compounds that inhibit colony formation
of BL/6, but not Cd93/, LSCs. MCP was tested in vitro and
in vivo and inhibited the expression of the target genes SCYL1,
TERT, and POLB and colony formation of murine and human
LSCs. In addition, MCP treatment, similar to blockade of CD93
signaling, prolonged survival of CML mice and reduced the
expression of genes related to stemness and myeloid differenti-
ation in LSCs. Because MCP is a very well-tolerated and cheap
anti-emetic drug, its efficacy to eliminate LSCs in CML patients
can be directly tested in clinical drug repurposing studies (e.g.,
in a TKI stop trial). In summary, CD93 signaling is a targetable
pathway to eliminate LSCs in CML.STAR+METHODS
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cards/RAMALHO_STEMNESS_UP
MA_MYELOID_DIFFERENTIATION_UP Ma et al., 2002 https://www.gsea-msigdb.org/gsea/msigdb/
cards/MA_MYELOID_DIFFERENTIATION_UP
ELDA software Hu and Smyth, 2009 http://bioinf.wehi.edu.au/software/elda/)





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Carsten
Riether (carsten.riether@dbmr.unibe.ch).
Materials availability
All unique reagent generated in this study are available from the Lead Contact without restriction.
Data and code availability
All RNA-seq data compiled for this study is made publicly available on the Gene Expression Omnibus (GEO) website (https://www.
ncbi.nlm.nih.gov/geo/) under the accession number GSE149358. This study does not include the development of new code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient samples
BM aspirates from untreated, newly diagnosed CML patients at the Department of Hematology and Central Hematology Laboratory,
Inselspital, Bern University Hospital and University of Bern, Switzerland, were obtained after written informed consent. BM from
healthy donors was collected from orthopedic patients who underwent Vertebroplasty. Patient characteristics are listed in Table
S3. Analysis of BM samples was approved by the local ethical committee of the Canton of Bern, Switzerland (KEK 122/14 and
2019-01627).
Cell lines
The leukemia cell line BCR-ABL1-expressing leukemia cell lines K562 (Chen, 1985) and EL-4 (Gorer, 1950) were purchased from
ATCC, the Platinum-E (Plat-E) Packaging Cell Line from Cell Biolabs (cat. RV-10) and the 293FT packaging cell line from Ther-
moFisher (cat. R70007). Therefore, no additional authentication was performed. The BM endothelial cell line STR-4 (Aizawa
et al., 1991) was kindly provided by Prof. M. Manz (University Hospital Z€urich, Switzerland). The cells line were tested myco-
plasma-free and was were grown in FCS-containing medium recommended by ATCC (http://www.atcc.org/?
geo_country=us) or by Cell Biolabs and ThermoFisher supplemented with 100U/ml penicillin, and 100 mg/ml of streptomycin
in a humidified atmosphere of 95% air and 5% CO2 at 37
C at a low passage number. Media were routinely changed every
3 days (Chen, 1985).
Mice
C57BL/6J (BL/6) mice were from Charles Rivers (Sulzfeld, Germany). Cd93/ on BL/6 background were provided by Prof. Hans
Acha-Orbea (University of Lausanne). BL/6 background was confirmed by SNP analysis performed at Taconic. Experiments were
performed with age- (6-8 weeks) and sex-matched animals of both genders. Mice were housed under specific pathogen–freee4 Cell Reports 34, 108663, January 26, 2021
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OPEN ACCESSconditions in individually ventilated cages with food and water ad libitum and were regularly monitored for pathogens. Animal exper-




In hypothesis-driven experimental designs, we addressed themolecular mechanisms ofCd93-signaling in LSCs in amurinemodel of
CML using BL/6 and Cd93/ mice and how Cd93-signaling can be pharmacologically targeted. In addition, leukemia development,
survival, LSC proliferation and LSC functionality was assessed. All experiments were performedwith 6- to 8-week-oldmice housed in
a specific pathogen-free facility in individually ventilated cages. Food was provided ad libitum. Mice were assigned randomly to
different treatment groups. These investigations were extended to CML cell lines and primary BM and leukapheresis samples
from newly diagnosed CML patients to further investigate the molecular mechanisms and demonstrate the human relevance of
the findings.
All experiments were conducted and analyzed in a non-blinded fashion. Information on biological and technical replicates are indi-
cated in figure legends.
Antibodies
Mouse: ac-kit-PE-Cy7 (cat. 105813, clone 2B8, 1:600), and -APC-Cy7 (cat. 105826, clone 2B8, 1:300), aSca-1-PerCP-Cy5.5 (cat.
108123, clone D7, 1:600), aCD16/32-PE-Cy7 (cat. 101318, clone 93, 1:200), aCD90.2-AlexaFluor 700 (cat. 105320, clone 30-H12,
1:100), aCD150-Pacific Blue (cat. 115923, clone TC15-12.2, 1:100), aCD127-PE (cat. 121111, clone SB/199, 1:100), aCD48-Alexa-
Fluor 700 (cat. 103425, clone HM48-1, 1:100), aGr-1-PE (cat. 108407, clone: RB6-8C5, 1:400), aGr-1-biotin (cat. 108404, clone RB6-
8C5, 1:300), aCD135-PE (cat. 135306, clone A2F10, 1:100), aCD19-APC-Cy7 (cat. 115530, clone 6D5, 1:300) and CD19-biotin (cat.
115503, clone 6D5, 1:300), aCD11b-PE-Cy7 (cat. 101216, clone M1/70, 1:200), aCD3ε-biotin (cat. 100304, clone 145-2C11, 1:300),
aTer119-biotin (cat. 116203, clone Ter-119, 1:300), aCD93-APC (cat. 136509, clone AA4.1, 1:200) and the corresponding isotype
control (cat. 400611, clone RTK4530) were from BioLegend. aCD34-eFluor 450 (cat. 48-0341-82, clone RAM34, 1:100) was from
Thermo Fisher. Streptavidin-BD Horizon V500 was from BD PharMingen (cat. 561419, 1:1000). Lineage depletion was performed
with a cocktail of lineage-specific antibodies (aCD3a-biotin, aCD19-biotin, aGr-1-biotin, aTer119-biotin, listed above in detail) using
abiotin microbeads and autoMACS system (Miltenyi Biotec).
Human: aCD34-APC (cat. 343608, clone 561, 1:80) and aCD34-APC-Cy7 (cat. 343513, clone 561, 1:100), aCD45-Pacific-Blue (cat.
304022, cloneHI30, 1:300),aCD38-PE-Cy7 (cat. 303515, cloneHIT2, 1:50) and aCD90-PerCP-Cy5.5 (cat. 328118, clone 5E10, 1:100)
were fromBioLegend. Lineage-positive cells were excluded by staining using biotinylated aCD2 (cat. 300204, clone RPA2.10, 1:100),
aCD3 (cat. 317320, clone OKT3, 1:100), aCD14 (cat. 325624, clone HCD14, 1:100), aCD16 (cat. 302004, clone 3G8, 1:100), aCD19
(cat. 302203, clone HIB19, 1:100), aCD56 (cat. 318320, clone HCD56, 1:100) and aCD235ab (cat. 306618, clone HIR2, 1:100) (Bio-
Legend), followed by a second step using streptavidin-BD-Horizon-V500 (cat. 561419, 1:1000, BD PharMingen). aCD93 (cat.
HPA009300, 1:50) was from Sigma. aCD93 (cat. ab134079, 1:1000) was from Abcam. Anti-rabbit IgG (H+L), F(ab’)2 Fragment Alex
Fluor 488 was from Cell signaling (cat. 4412, 1:1000). Goat-anti-rabbit Alexa647 secondary antibody was from Thermo Fisher Scien-
tific (cat. A32733, 1:2000). Fixable viability dye-eFluor450 (cat. 65-0863-14, 1:4000) and eFluor780 (cat. 65-0865-14, 1:5000)was from
Thermo Fisher Scientific
Samples were acquired on a BD LSRFortessa and sorting procedures were conducted using a BD FACS Aria III (BD Biosciences).
Data were analyzed using FlowJo software v.10.6 (TreeStar).
All primary antibodies for Western Blot were purchased from Abcam: aGFP (cat. ab290, 1:1000), a-lamin B1 (cat. Ab16048,
1:1000), a-alpha tubulin (DM1A) (cat. ab7291, 1:1000). All secondary antibodies were purchased from Cell signaling: a-mouse IgG
(cat. 7076, 1:10000), arabbit IgG (cat. 7074, 1:10000).
Colony assays
Colony assays from BM lin- cells of CML and naive mice and CD34+ stem/progenitor cells of human CML patients were performed as
described before (Riether et al., 2015c).
For mouse colony assays 103 FACS-purified LSKs or LSCs were plated in methylcellulose (cat. 03134, STEMCELL Technologies)
and colonies were enumerated 7 days later. For serial re-plating experiments, 104 cells were collected from preceding colony assays
and replated in methylcellulose. Colonies were enumerated after seven days.
For the drug library screen, we used compounds from the Screen-Well FDA Approved Drug Library V2 version 1.2 (cat. BML-
2843-0100, Enzo, Table S2). For this assay, 103 FACS-purified murine LSCs were incubated overnight in 96 well V-bottom plates
in the presence of 1 mM compound (Table S2) or vehicle followed by plating methylcellulose. Colonies were enumerated after seven
days.
For experiments using metoclopramide (cat. M0763, Sigma), 103 FACS-purified murine LSCs or 2x103 human CD34+ stem/pro-
genitor cells were incubated overnight in 96 well V-bottom plates in the presence of 0.1 and 1 mM metoclopramide, 5 mM nilotinib
or vehicle followed by plating methylcellulose. Colonies were enumerated 7 days and 14 days later, respectively.Cell Reports 34, 108663, January 26, 2021 e5
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replated in methylcellulose in the absence of any compound. Colony were enumerated 7 days and 14 days later.
Gene silencing of CD93, Cd93 and Scyl1
siRNA: HumanCD93 andmurine Scyl1 genes were silenced in human lin-CD90+CD34+ BM cells and murine LSCs respectively using
siRNA and esiRNA according to the manufacturer’s instructions (Santa Cruz Biotechnology (cat. sc-105157) and Sigma (cat.
EMU022211), respectively) with minor modifications to increase silencing efficiency. Briefly, siRNA, esiRNA or scrambled controls
were mixed with transfection medium and Lipofectamine LTX (cat. 15338500, Thermo Fisher Scientific) in serum-free transfection
media. Cells were subsequently treated with transfection complexes in the presence of antibiotic-free growth medium overnight
and were further used for functional assays and determination of the expression for selected genes of interest.
shRNA: Cd93 mRNA was silenced in murine LSCs using ready-to-use lentiviral particles (shCd93: cat. sc-106980-V; scr: cat. sc-
108080, Santa Cruz Biotechnology). Briefly, 5x104 LSCs cells were transduced overnight by spin-transfection at 37C and 5% CO2
with virus of shCd93 lentiviral particles or the respective control scrambled RNA lentiviral particles (MOI: 5, Santa Cruz Biotechnology
Inc.) in the presence of 5 mg/ml polybrene (cat. H9268, Sigma). After spin transfection, mediumwas removed, and cells were cultured
in medium supplemented with 1 mg/ml puromycin (cat. P8833, Sigma) for 48h to select for stable expression of shCd93 or scrambled
(scr) RNA.
Overexpression of mCd93
The mouse Cd93 gene (ENSMUSG00000027435; mCd93) was cloned from FACS-purified B cell precursors. cDNA synthesis was
carried out using SuperScript III Reverse Transcriptase kit (cat. 18080085, Thermo Fisher Scientific). The open reading frame
(ORF) of Cd93 with a total length of 1.932kb (644aa) was amplified by PCR using tagged primes for the restriction enzymes (EcoRI
and XhoI, cat. R0101M and R0146M, New England BioLabs). In addition, the forward primer harbored the Kozak consensus
sequence (GCCACC) before the start codon to enhance the protein translation. Next, the Cd93 ORF was cloned into pMSCV-
IRES-GFP II (pMIG II) plasmid (Holst et al., 2006)(cat. 52107, Addgene).
TheCd93intra construct, lacking the sequence encoding for the extracellular domain of Cd93was designed by cloning of the signal
peptide (1-22aa), transmembrane (574-598aa) and cytoplasmic (599-644aa) domains of the Cd93 ORF (total length of 282bp) into a
pMIG II plasmid. To predict and select the different Cd93 protein domains prior to cloning we used the Phobius database (https://
phobius.sbc.su.se/).
Retroviral vectors expressing Cd93 or Cd93intra were generated using Platinum-E (Plat-E) Packaging Cell Line (Cell Biolabs). Next,
FACS-purified murine LSKs or CML LSCs derived from BL/6 and/or Cd93-/- mice were transduced with retroviral vectors expressing
Cd93, Cd93intra or an empty vector as a control (mock). Two days after transduction, LSCs or LSKs expressing Cd93, Cd93intra or
mock GFP were FACS-purified and plated in methylcellulose.
Overexpression of Scyl1
The mouse Scyl1 gene (ENSMUSG00000024941;mScyl1) was sub-cloned from the SCYL1 Gene ORF cDNA clone (cat. MG51756-
NM, Sino Biological). cDNA synthesis was carried out using SuperScript III Reverse Transcriptase kit (cat. 18080085, Thermo Fisher
Scientific). The open reading frame (ORF) of Scyl1 with a total length of 2.4kb (289aa) was amplified by PCR using tagged primes for
the restriction enzymes (EcoRI and XhoI, cat. R0101M and R0146M, New England BioLabs). In addition, the forward primer harbored
the Kozak consensus sequence (GCCACC) before the start codon to enhance the protein translation. Next, the mScyl1 ORF was
cloned into pMSCV-IRES-GFP II (pMIG II) plasmid (cat. 52107, Addgene).
Retroviral vectors expressing Scyl1 were generated using Platinum-E (Plat-E) Packaging Cell Line (Cell Biolabs). Next, FACS-pu-
rifiedmurine CML LSCs derived from BL/6 and/orCd93-/- mice were transduced with retroviral vectors expressing Scyl1 or an empty
vector as a control (mock). Two days after transduction, LSCs expressingScyl1 ormockGFPwere FACS-purified and plated inmeth-
ylcellulose. Successful overexpression of Scyl1 was assessed by qRT-PCR analysis.
Sub-cellular localization of mCd93
ThemouseCd93 gene was cloned in pAcGFP1-N1mammalian expressing plasmid and as the lentiviral construct pLVX-AcGFP1-N1
(cat. 632154, Clontech). Lentiviral particles (3rd generation) were generated into the 293FT packaging cell line (cat. R70007, Thermo
Fisher Scientific) using pMDLg/pRRE, pRSV-Rev and pCMV-VSV-G plasmids (Dull et al., 1998)(Addgene). For transfection, adherent
STR-4 cells were seeded at density 105 cells/well in antibiotics-free medium and left to adhere for 5h. Cells growing in suspension
(K562 and EL4 cells) were seeded at a density 105 cells/well in antibiotics-free medium shortly before transfection. Liposomal trans-
fection was performed with Lipofectamine LTX according to the manufacturers’ instructions (cat. 15338500, Thermo Fisher Scien-
tific), using the previously optimized conditions (per 105 cells: 0.25 mg plasmid DNA, 2.5 mL Lipofectamine LTX, and for K562 addi-
tionally 0.25 mL PLUS reagent). 48h post transfection/transduction, the expression of mCD93-GFP fusion protein was analyzed by
ImageStream or Western Blot. For experiments with nilotinib, 70 mM of nilotinib or vehicle (DMSO) were added to the culture for
72h. For experiments using the PKC-a/b inhibitor PKC 20-28 (cat. 476480, Merck Millipore) or metoclopramide (cat. M0763, Sigma),
50 mM and 0.1 mM of compound or vehicle (H20) were added to the culture for 72h, respectively.e6 Cell Reports 34, 108663, January 26, 2021
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Briefly, cells expressing CD93-GFP were stained with fixable viability dye eFluor780 (cat. 65-0865-14, 1:5000, Thermo Fisher Scien-
tific) for 30 min at 4C. Cells were subsequently fixed with 4% paraformaldehyde for 10 min at room temperature and then permea-
bilized for 5 min at room temperature with DAKO Wash (cat. S300685-2, Dako) diluted in DAKO diluent (cat. S0809, Dako). After
washing, nuclei were stained with 10 mg/ml DAPI (cat. D1306, Thermo Fisher Scientific) or NucRed Live 647 ReadyProbes (cat.
R37106, Thermo Fisher Scientific) according to the manufacturers’ instructions. Data was acquired on the Amnis ImageStreamX
Mark II instrument (Merck Millipore). Spectral compensation, background correction and adaption of the nuclear mask was per-
formed, and images were analyzed with the IDEAS image analysis software by calculating nuclear translocation of GFP-labeled
CD93. A minimum 1200 GFP+ cells were analyzed per sample unless otherwise specified in the Figure legends.
To address nuclear CD93 expression in human CD34+ CML stem/progenitor cells and K562 and STR-4 cell lines, cells were
sequentially stained after fixation and permeabilization prior to staining with aCD93 (cat. ab134079, 1:1000) and anti-rabbit IgG
(H+L), F(ab’)2 Fragment Alex Fluor 488 was from Cell signaling (cat. 4412, 1:1000) both diluted in DAKO diluent (cat. S0809, Dako).
Sub-cellular fractionation and Western Blot
After the FACS-sorting, K562 cells expressing pLVX-AcGFP1-N1 or pLVX-AcGFP1-N1-Cd93were washed twice with ice-cold PBS.
The cell pellet was re-suspended in 0.1%NP40 (cat. 28324, Thermo Fisher Scientific)-PBS. An aliquot was removed as the whole cell
lysate. The remaining lysate was centrifuged for 10 s. and the supernatant was transferred to a new tube as the cytoplasmic fraction.
The pellet was re-suspended in ice-cold NP40-PBS followed by the centrifugation. The supernatant was discarded, and the remain-
ing pellet was kept as a nuclear fraction. The whole cell lysate and the nuclear fraction were re-suspended in 1x Laemmli buffer (cat.
610747, Biorad) containing b- mercaptoethanol followed by sonication using microprobes 5x for 2 s. at 40% intensity. The cyto-
plasmic fraction was resuspended in Laemmli buffer; all samples were boiled for 5min and loaded on the 4%–20%Mini-PROTEAN
TGXStain-Free Protein Gels (cat. 4568096, Biorad). The transfer was performed using Trans-Blot Turbo RTAMini PVDF Transfer Kit
(cat. 1704272, Biorad). The membranes were blocked for 2h in 5% BSA and incubated overnight, at 4C, with the following anti-
bodies: aGFP (cat. ab290, abcam, 1:1000), a-lamin B1 (cat. Ab16048, Abcam, 1:1000) and a-alpha tubulin (DM1A) (cat. ab7291, Ab-
cam, 1:1000). The membranes were incubated with HRP conjugated secondary antibodies: a-mouse IgG (cat. 7076, Cell signaling,
1:10000) or a-rabbit IgG (cat. 7074, Cell signaling, 1:1000). Proteins were detected with ClarityWestern ECL Substrate (cat. 1705060,
Biorad) and visualized on ChemiDoc Imaging Systems.
Immunohistochemistry (IHC)
IHC stainings were performed on a Leica BONDRX automated immunostainer (Leica Biosystems). Thin sections (1-2 mm) of formalin-
fixed paraffin-embedded (FFPE) tissue were pre-treated by boiling at 100C in citrate buffer, pH 6.0 for 30min. Double stainings were
performed sequentially: First, slides were stained with rabbit anti-human CD93 (polyclonal, Sigma #HPA012368; dilution 1:50) for
30 min, followed by visualization using the Bond Polymer Refine DAB Detection kit (cat. DS9800, Leica Biosystems). Then, slides
were counterstained usingmouse anti-human CD34 (clone QBEnd/10, Cell Marque cat. 134M-16; dilution 1:200) for 15min, followed
by visualization using the Bond Polymer Refine RedDetection kit (cat. DS9390, Leica Biosystems). Finally, the sampleswere counter-
stained with hematoxylin and mounted with Aquatex (cat. 108562, Merck Millipore). Slides were digitized using a Pannoramic 250
Flash III scanner (3DHistech). Analysis and quantification of the stainings was performed under the supervision of a board-certified
surgical pathologist (C.M.S.).
High-throughput transcriptome analysis using next generation RNA sequencing (RNA-Seq)
Total RNA was extracted from naive BL/6 and CD93/ LSKs (n = 2/group) and BL/6 LSCs isolated from primary CML mice (n = 3/
group) that were subjected to in vivo treatment with either vehicle or MCP (10mg/kg) using the RNeasy Micro Kit (cat. 74004,
QIAGEN). Total RNA quality was determined by a Bioanalyzer using the RNA 6000 Nano Chip (Agilent Technologies) and quantified
by fluorometry using the Quantifluor RNA System Kit (cat. E3310, Promega) on a Quantus Fluorometer Instrument (Promega).
Library preparation was performed from total RNA using the SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara Bio).
Libraries were quality-checked on the Fragment Analyzer using the High Sensitivity NGS Fragment Analysis Kit (Agilent). Samples
were pooled to equal molarity and the pool was quantified by fluorometry, in order to be loaded at a final concentration of 2pM
on the NextSeq 500 instrument (Illumina). Samples were sequenced SR76 using the NextSeq 500 High Output Kit 75-cycles (Illumina)
and primary data analysis was performed using the Illumina RTA version 2.4.11 and bcl2fastq v2.20.0.422.
RNA-Seq data analysis
The RNA-Seq data was assembled by SeqMan NGen software v.15 and analyzed using ArrayStar software v.15 (DNASTAR, USA).
The level of gene expression was assessed after normalization and log2 transformation. The dataset was analyzed by two-way
ANOVA. Genes with significant difference in their expression at FDR-p < 0.05 and fold differences R 1.5 were selected. Data
were clustered using standard Euclidean’s method based on the average linkage and heatmaps were generated according to the
standard normal distribution of the values.Cell Reports 34, 108663, January 26, 2021 e7
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GO enrichment was assessed using Partek Genomics SuiteTM software, v.7 (Partek). The list of differently expressed genes was
grouped into functional hierarchies. Enrichment scores were calculated using a chi-square test comparing the proportion of the
gene list in a group to the proportion of the background genes. A value of 3 or higher corresponded to a significant overexpression
(p < 0.05). GSEA was performed using GSEA software v.3.0 (Broad Institute). Enrichment analysis was assessed for all pathway-
related genes acquired from pathcards database (https://pathcards.genecards.org/) and the gene sets RAMALHO_STEMNESS_UP
(Ramalho-Santos, 2002) and MA_MYELOID_DIFFERENTIATION_UP (Ma et al., 2002).
qRT-PCR
Total RNA was extracted from FACS-sorted human CD34+ LSCs, murine LSCs or LSKs using the RNeasy Micro Kit (cat. 74004,
QIAGEN). For each sample, cDNA synthesis was assessed using High Capacity cDNAReverse Transcription Kit (cat. 4368814, Ther-
moFisher). Primers were designed for each gene using Primerquest Software (Integrated DNA Technologies). For qRT-PCR analysis,
synthesized cDNAs amplified with specific primers using FastStart Universal SYBR Green 2X PCR Master Mix (cat. 04913850001,
Roche). Raw values were normalized using geometric mean of reference genes (ACTB and GAPDH). Real-time PCR reactions were
performed in replicates and included no-template controls using ABI Prism 7500 Sequence Detection System (Applied Biosystems).
The fold difference for each sample was calculated using the comparative Ct method. The following primer pairs were used to deter-
mine mRNA expression of respective genes in human CD34+ LSCs, murine LSCs or LSKs are depicted in Table S4.
CML model
FACS-purified LSKs were harvested and transduced twice with BCR-ABL1-GFP or -CFP retrovirus by spin infection at a multiplicity
of infection (MOI) of 0.5. 3x104 cells were injected intravenously (i.v.) into the tail vein of non-irradiated syngeneic recipients. To deter-
mine residual disease in survivingmice, CMLmice were sacrificed 90 days after transplantation and 5x106 BM cells were injected i.v.
into lethally irradiated (2 3 6.5 Gy) recipient mice.
For MCP treatment (prophylactic setting), CMLmice were treated daily once p.o. with MCP (Sigma) at a concentration of 10mg/kg
(Shalaby et al., 2013) starting at the day of CML induction.
ForMCP treatment (therapeutic setting), BL/6 CMLmicewere randomized at day 13 after leukemia induction andwere treatedwith
either vehicle or MCP (10mg/kg) for 3 days. At day 16, mice were sacrificed, and BM LSCs of individual mice were FACS-purified and
subjected to RNA sequencing analysis.
LSPC and HSPC analysis
LSCP numbers in CMLmice anHSCP numbers in naivemicewere analyzed as described before (Riether et al., 2015b; Sch€urch et al.,
2014).
LSC homing experiments
5x104 BL/6 or Cd93/ LSCs were transplanted i.v. into lethally irradiated (2 3 6.5Gy) or non-irradiated BL/6 mice. 14h later mice
were sacrificed, and BM was analyzed for the presence of GFP+ LSCs.
BrdU incorporation in vivo
CML mice were injected i.p. with 1 mg BrdU (cat. B5002, Sigma). 14 h later, mice were sacrificed and BrdU staining was performed
using the BD PharMingen BrdU Flow Kit according to the manufacturer’s instructions (cat. 552598).
QUANTIFICATION AND STATISTICAL ANALYSIS
All flow cytometry, in vitro and in vivo datawere analyzed and plotted usingGraphPad Prism software v7.0 (GraphPad). Bars and error
bars indicatemeans and standard deviations of the indicated number of independent biological replicates, respectively, if not otherwise
specified. Two-tailed Student’s t test, one-way-ANOVA followed by Dunnett’s or Tukey’s post-test, two-way ANOVA followed by Bon-
ferroni post-test were used as indicated in the legends. LSC frequencies with 95% confidence intervals (CI) were estimated with ELDA
software (http://bioinf.wehi.edu.au/software/elda/) andsignificantdifferences inLSCfrequencywerecalculatedbyc2 test in limitingdilu-
tionassaysaccording to (HuandSmyth, 2009).Significanceofdifferences inKaplan-Meier survival curveswasdeterminedusing the log-
rank test (two-tailed). p < 0.05 was considered significant. Details on the quantification, normalization and statistical tests used in every
experiment can be found in the corresponding figure legend. n represents the number of independent replicates in each experiment.e8 Cell Reports 34, 108663, January 26, 2021
